Logo image of VNRX

VOLITIONRX LTD (VNRX) Stock Fundamental Analysis

NYSEARCA:VNRX - NYSE Arca - US9286611077 - Common Stock - Currency: USD

0.5389  +0.01 (+2.12%)

After market: 0.5129 -0.03 (-4.82%)

Fundamental Rating

2

Overall VNRX gets a fundamental rating of 2 out of 10. We evaluated VNRX against 188 industry peers in the Health Care Equipment & Supplies industry. VNRX may be in some trouble as it scores bad on both profitability and health. VNRX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VNRX had negative earnings in the past year.
VNRX had a negative operating cash flow in the past year.
In the past 5 years VNRX always reported negative net income.
VNRX had a negative operating cash flow in each of the past 5 years.
VNRX Yearly Net Income VS EBIT VS OCF VS FCFVNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -281.97%, VNRX is not doing good in the industry: 96.28% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -281.97%
ROE N/A
ROIC N/A
ROA(3y)-192.89%
ROA(5y)-150.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VNRX Yearly ROA, ROE, ROICVNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

VNRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VNRX Yearly Profit, Operating, Gross MarginsVNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

0

2. Health

2.1 Basic Checks

VNRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VNRX has more shares outstanding
VNRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VNRX has a worse debt to assets ratio.
VNRX Yearly Shares OutstandingVNRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VNRX Yearly Total Debt VS Total AssetsVNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

VNRX has an Altman-Z score of -47.62. This is a bad value and indicates that VNRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -47.62, VNRX is doing worse than 94.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -47.62
ROIC/WACCN/A
WACC8.69%
VNRX Yearly LT Debt VS Equity VS FCFVNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.40 indicates that VNRX may have some problems paying its short term obligations.
VNRX has a Current ratio of 0.40. This is amonst the worse of the industry: VNRX underperforms 94.68% of its industry peers.
VNRX has a Quick Ratio of 0.40. This is a bad value and indicates that VNRX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.40, VNRX is doing worse than 94.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.4
VNRX Yearly Current Assets VS Current LiabilitesVNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.30% over the past year.
VNRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 62.43%.
VNRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 128.05% yearly.
EPS 1Y (TTM)41.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)62.43%
Revenue growth 3Y139.31%
Revenue growth 5Y128.05%
Sales Q2Q%43.41%

3.2 Future

Based on estimates for the next years, VNRX will show a very strong growth in Earnings Per Share. The EPS will grow by 60.41% on average per year.
VNRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 155.02% yearly.
EPS Next Y57.23%
EPS Next 2Y37.89%
EPS Next 3Y59.91%
EPS Next 5Y60.41%
Revenue Next Year346.89%
Revenue Next 2Y241.15%
Revenue Next 3Y279.51%
Revenue Next 5Y155.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VNRX Yearly Revenue VS EstimatesVNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
VNRX Yearly EPS VS EstimatesVNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VNRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNRX Price Earnings VS Forward Price EarningsVNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNRX Per share dataVNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

VNRX's earnings are expected to grow with 59.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.89%
EPS Next 3Y59.91%

More info and screens

0

5. Dividend

5.1 Amount

VNRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOLITIONRX LTD

NYSEARCA:VNRX (6/3/2025, 5:05:00 PM)

After market: 0.5129 -0.03 (-4.82%)

0.5389

+0.01 (+2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners20.36%
Inst Owner Change12.08%
Ins Owners8.19%
Ins Owner Change11.37%
Market Cap55.52M
Analysts80
Price Target3.22 (497.51%)
Short Float %0.42%
Short Ratio1.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.51%
Min EPS beat(2)-30.72%
Max EPS beat(2)-2.3%
EPS beat(4)2
Avg EPS beat(4)-3.4%
Min EPS beat(4)-30.72%
Max EPS beat(4)17.44%
EPS beat(8)5
Avg EPS beat(8)2.52%
EPS beat(12)8
Avg EPS beat(12)3.37%
EPS beat(16)9
Avg EPS beat(16)-53.2%
Revenue beat(2)0
Avg Revenue beat(2)-72.59%
Min Revenue beat(2)-73.81%
Max Revenue beat(2)-71.37%
Revenue beat(4)0
Avg Revenue beat(4)-48.09%
Min Revenue beat(4)-73.81%
Max Revenue beat(4)-18.52%
Revenue beat(8)0
Avg Revenue beat(8)-46.4%
Revenue beat(12)0
Avg Revenue beat(12)-51.42%
Revenue beat(16)0
Avg Revenue beat(16)-56.25%
PT rev (1m)0%
PT rev (3m)-5.54%
EPS NQ rev (1m)-21.43%
EPS NQ rev (3m)15%
EPS NY rev (1m)0%
EPS NY rev (3m)23.53%
Revenue NQ rev (1m)-33.7%
Revenue NQ rev (3m)-54.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-27.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.43
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.01
BVpS-0.27
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -281.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-192.89%
ROA(5y)-150.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.09%
Cap/Sales 37.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.4
Altman-Z -47.62
F-Score3
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)104.21%
Cap/Depr(5y)136.83%
Cap/Sales(3y)230.92%
Cap/Sales(5y)4234.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y57.23%
EPS Next 2Y37.89%
EPS Next 3Y59.91%
EPS Next 5Y60.41%
Revenue 1Y (TTM)62.43%
Revenue growth 3Y139.31%
Revenue growth 5Y128.05%
Sales Q2Q%43.41%
Revenue Next Year346.89%
Revenue Next 2Y241.15%
Revenue Next 3Y279.51%
Revenue Next 5Y155.02%
EBIT growth 1Y31.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.78%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.92%
OCF growth 3YN/A
OCF growth 5YN/A